Freshworks (FRSH) Q3 2026 Earnings Call Transcript

Freshworks reported Q3 revenue of $245.4 million, up 14% year over year, while non-GAAP operating income rose to $73.2 million, a 29.8% margin, and adjusted free cash flow reached $73.9 million. The company raised full-year 2026 revenue guidance to $965 million–$966 million and expects approximately $265 million in adjusted free cash flow; it also said it crossed $1 billion in ARR in October. EX ARR grew 22% on a constant-currency basis to $588 million, while management cited lengthening sales cycles for larger deals and expected less upfront term-license revenue as customers transition to cloud ITAM.

Analysis

FRSH’s key tension is growth quality, not the headline margin beat. The upmarket shift supports larger contracts and platform cross-sell, but longer sales cycles make pipeline conversion less predictable; the 11% billings growth versus 14% revenue growth is a watch item, not proof of deterioration. Watch whether EX growth reaccelerates organically: the year-end ARR outlook includes $8–10 million from acquisitions, while cloud ITAM adoption and planned ITOM integration are still early. The move from upfront on-prem term licenses to ratable cloud revenue can also depress near-term reported growth even if customer economics improve.

The 106% company-wide NDR excluding legacy Device42 customers—and lower EX NDR than the prior quarter—tempers the claim that AI and multiproduct adoption are already driving broad expansion. The >115% NDR for AI buyers is company-reported and may reflect customer selection; it needs to show up in cohort retention and paid-product penetration. Freshworks’ platform pitch could help displace ServiceNow and Atlassian in agile enterprises, while Zendesk is more directly relevant to CX; however, CX remains a slower-growth business, so it is not yet a consolidated growth engine. CDW may benefit as a channel partner, but one disclosed deal is not material evidence of a company-wide earnings tailwind.

Near term, buybacks and cash generation may support sentiment, but they do not resolve organic growth uncertainty. Over 1–3 months, focus on Q4 conversion, organic EX ARR, billings, and NDR. Over 6–18 months, cloud ITAM/ITOM expansion and FedRAMP certification are catalysts; delays, weaker expansion, or continued sales-cycle elongation would challenge the mid-20s EX growth thesis.

Key Decisions for Investors

• FRSH: Do not chase the post-earnings move. Consider a starter long only on post-call weakness if Q4 pipeline converts and organic EX growth remains consistent with management’s mid-20s ambition; reassess if billings growth remains below revenue growth or EX NDR deteriorates further.
• Track organic versus acquired ARR separately, alongside paid ITAM/ITOM attach rates and renewal cohorts. Treat AI-driven retention as unproven until cohort disclosures corroborate the >115% claim across a broader customer base.
• Catalyst watch: Q4 results and 2027 guidance, with particular attention to sales-cycle duration, expansion contribution, and the cloud-license revenue transition. A FedRAMP delay beyond the company’s stated end-of-summer 2027 expectation would weaken the government-market optionality.
• CDW: No standalone trade from the disclosed partner activity; monitor whether partner-sourced business broadens and becomes material to CDW’s reported results.